Back

HFWM: exploring biomarkers in chronic thromboembolic pulmonary hypertension (CTEPH): prognostic significance, and post-PEA dynamics analysis

12 May 2024 (15:00 - 17:00)
Organised by: Logo
Congress Presentation Part of: ePosters in valvular and pulmonary 4 Pulmonary Hypertension HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Alessandra Cuomo

University of Naples Federico II, Naples (Italy)

3 More presentations in this session

Presentation thumbnail
Exploring the clinical relevance of TSAT <21% as an iron deficiency indicator in pulmonary arterial hypertension: a comparative analysis with alternative criteria and existing guidelines
Doctor N. Ilchyshyn (Almada, PT)
Abstract Slides Video
Presentation thumbnail
Long-term survival outcomes and baseline hemodynamics in patients with PAH versus CTEPH
Doctor J. Mesquita Guimaraes (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Real-world results of selexipag in treating pulmonary hypertension in a portuguese population
Doctor J. Mesquita Guimaraes (Coimbra, PT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in valvular and pulmonary 4

The Event

Event poster

Heart Failure 2024

12 May 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Circulating Angiopoietin-2 (Angpt2) levels predict diagnosis of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
thumbnail
Congress Session
Diagnosis and therapy of chronic thromboembolic pulmonary hypertension
thumbnail
Congress Session
Pulmonary circulation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources